Aims This study aimed to observe the efficacy and safety of anlotinib in the treatment of small
cell lung cancer (SCLC) in the real world, as first-line maintenance therapy, second-line, and …

Background: Anlotinib demonstrated promising efficacy for patients with extensive-stage
small-cell lung cancer (ES-SCLC) in clinical trials. However, the real-world evidence of …

Background Anlotinib significantly extended progression‐free survival (PFS) and overall
survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. Methods In this …

Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …

Purpose As a novel antiangiogenic multi-target tyrosine kinase inhibitor recently approved in
China, anlotinib has exhibited promising anticancer efficacy and acceptable safety profile in …

Purpose Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown
favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell …

Introduction Extensive stage small cell lung cancer (ES-SCLC) is associated with poor
prognosis. Recently, anlotinib has demonstrated significant clinical activity as a third-line or …

Methods This study included 55 advanced SCLC patients (n= 28 for anlotinib group and n=
27 for chemotherapy group) from Shanghai Chest hospital between January 2017 and …

Background Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very
poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients …

Background Patients with extensive-stage small-cell lung cancer (ES-SCLC) have high
recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the …